Jamieson N V, Friend P J, Johnston P S, Alexander G, Calne R
University of Cambridge, Department of Surgery, Addenbrooke's Hospital, England.
Clin Transpl. 1991:119-25.
Liver grafting is now established as the optimal treatment for patients with end-stage parenchymal liver disease. Twenty-three years of experience at a single center is presented. The 1-year actuarial patient survival rate for all cases transplanted in Cambridge has now risen from 10% in 1968 to 1970 to 80% in 1990 to 1991. Increasing numbers of patients are being referred for transplantation with an ever-increasing range of indications being developed. Many inborn errors of metabolism can now be cured by liver grafting. There is still, however, considerable scope for improvement in many areas of patient treatment from operative and postoperative care to long-term immunosuppressive management. Much remains to be done to minimize early sepsis- and rejection-related deaths and late immunosuppression-related morbidity.
肝移植现已成为终末期实质性肝病患者的最佳治疗方法。本文介绍了一个中心23年的经验。剑桥所有移植病例的1年精算患者生存率现已从1968年至1970年的10%上升至1990年至1991年的80%。越来越多的患者因不断扩大的适应症范围而被转诊进行移植。现在许多先天性代谢缺陷可以通过肝移植治愈。然而，从手术和术后护理到长期免疫抑制管理，患者治疗的许多方面仍有很大的改进空间。为尽量减少早期败血症和排斥反应相关死亡以及晚期免疫抑制相关发病率，仍有许多工作要做。
